



Attorney Docket No.: MSK.P-067

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Norton
Serial No.: 10/735,180
Confirmation:
Filed: 12/12/2003
Title: Dose-Dependent and Sequential Adjuvant Breast Cancer Chemotherapy

SUBMISSION OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant requests that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith.

No fee is believed to be due with this paper as we have not received an action on the merits. However, the Commissioner is authorized to charge any additional fees which might be due to Deposit Account No. 15-0610.

Respectfully submitted,
OPPEDAHL & LARSON LLP

Marina T. Larson

Marina T. Larson, Ph.D., Reg. No. 32,038
P.O. Box 5068
Dillon, CO 80435-5068
Ph.: 970-468-6600 Fax: 970-468-0104

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this paper and the attachments mentioned herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on


March 11, 2004

Anne Wagner

Anne Wagner

March 11, 2004

Date of Signature



Complete if Known

(Use as many sheets as necessary)

1

•

C

10/735 180

12/12/2003

Norton

--	--

--	--

MSK.P-067

[illegible][illegible]Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 2 of 9	Attorney Docket Number	MSK.P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AGHAJANIAN ET AL, Phase II Study of Dose-Dense High-Dose Chemotherapy Treatment with Peripheral-Blood Progenitor-Cell Support as Primary Treatment for Patients with Advanced Ovarian Cancer, Journal of Clinical Oncology, 1998, Page(s) 1852-1860, Volume 16, Number 5	
		BHARDWAJ ET AL, An Intensive Sequenced Adjuvant Chemotherapy Regimen for Breast Cancer, Cancer Investigation, 1993, Page(s) 6-9, Volume 11	
		BUDMAN ET AL, Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer, Journal of the National Cancer Institute, 1998, Page(s) 1205-1211, Volume 90, Number 16	
		CITRON ET AL, Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 8741, Journal of Clinical Oncology, 2003; Page(s) 1431-1439; Volume 21; Number 8	
		COSTANZA ET AL, Safety and Efficacy of Using a Single Agent or a Phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized Study-Cancer and Leukemia Group B 8642, Journal of Clinical Oncology, 1999, Page(s) 1397-1406, Volume 17, Number 5	
		CROWN ET AL, Rapid Delivery of Multiple High-Dose Chemotherapy Courses with Granulocyte Colony-Stimulating Factor and Peripheral Blood-Derived Hematopoietic Progenitor Cells, Journal of National Cancer Institute, 12/16/1992, Page(s) 195-1936, Volume 84, Number 24	
		CROWN ET AL, Rapid Administration of Multiple Cycles of High-Dose Myelosuppressive Chemotherapy in Patients with Metastatic Breast Cancer, Journal of Clinical Oncology, 1993, Page(s) 1144-1149, Volume 11, Number 6	
		CROWN ET AL, High-Intensity Chemotherapy with Hematopoietic Support in Breast Cancer, Pisa Symposia in Oncology: From Biology to Therapy, 1993, Page(s) 378-388, Volume 698	
		CROWN ET AL, High-dose Chemotherapy of Breast Cancer: Current Status and Developmental Strategies, European Journal of Cancer, 1995, Page(s) 809-811, Volume 31A, Number 5	
		CROWN ET AL, Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer; 1995; Page(s) 21-26; Number 6	
		CROWN ET AL, High-dose chemotherapy of breast cancer, Supplement of The Canadian Journal of Oncology, 1995, Page(s) 80-82, Volume 5, Number 1	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 3 of 9	Attorney Docket Number	MSK.P-067	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FENNELLY, Simultaneous Dose Escalation and Schedule Intensification of Carboplatin-based Chemotherapy Using Peripheral Blood Progenitor Cells and Filgrastim: A Phase I Trial, Cancer Research, 12/1/1994, Page(s) 6137-6142, Volume 54	
		FENNELLY ET AL, Clinical Potential of Hemopoietic Growth-Factor Support for High-Dose Chemotherapy, 1996, Page(s) 299-311, Publisher: Cambridge University Press	
		FENNELLY ET AL, Phase I and Pharmacologic Study of Paclitaxel Administered Weekly in Patients with Relapsed Ovarian Cancer, Journal of Clinical Oncology, 1997, Page(s) 187-192, Volume 15, Number 1	
		FENNELLY ET AL, High-intensity Chemotherapy with Peripheral Blood Progenitor Cell Support, Seminars in Oncology, 4/1994, Page(s) 21-25, Volume 21, Number 2	
		FENNELLY ET AL, Dose Escalation of Paclitaxel with High-Dose Cyclophosphamide, with Analysis of Progenitor-Cell Mobilization and Hematologic Support of Advanced Ovarian Cancer Patients Receiving Rapidly Sequenced High-Dose Carboplatin/Cyclophosphamide Courses, Journal of Clinical Oncology, 5/1995, Page(s) 1160-1166, Volume 13, Number 5	
		FORNIER ET AL, Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide versus Concurrent Paclitaxel and Cyclophosphamide: 5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma, Clinical Cancer Research, 2001, Page(s) 3934-3941, Volume 7	
		GILEWSKI ET AL, Cytokinetics of Neoplasia, The Molecular Basis of Cancer, 1995, Page(s) 143-159	
		GILEWSKI ET AL, Cytokinetics and Breast Cancer Chemotherapy, Diseases of Breast Cancer, 1995, Page(s) 751-768	
		GILEWSKI ET AL, Cytokinetics, Principles of Chemotherapy, 2000, Page(s) 511-538	
		HENDERSON ET AL; In Reply to: Benefit of Paclitaxel in Estrogen Receptor-Negative Versus Estrogen Receptor-Positive Early Breast Cancer; Journal of Clinical Oncology; 2003; Page(s) 4465-4466	
		HENDERSON ET AL, Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy Regimen for Patients with Node-Positive Primary Breast Cancer, Journal of Clinical Oncology, 3/15/2003, Page(s) 976-983, Volume 21, Number 6	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/735,180		
		Filing Date	12/12/2003		
		First Named Inventor	Norton		
		Art Unit			
		Examiner Name			
Sheet	4	of	9	Attorney Docket Number	MSK.P-067

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HUDIS ET AL, Dose-Intensive Sequential Crossover Adjuvant Chemotherapy for Women with High Risk Node-Positive Primary Breast Cancer, Adjuvant Therapy of Cancer, 1993, Page(s) 214-219	
		HUDIS ET AL, Event-Free Survival After Sequential Dose-Dense Doxorubicin (A), Paclitaxel (T) and Cyclophosphamide (C) in women (pts) with > 4 Positive (+) Axillary Lymph Nodes (LN), Breast Cancer Research Treatment, 1996, Page(s) 232, Volume 41	
		HUDIS ET AL, Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel, Cancer Investigation, 1998, Page(s) 67-71, Volume 16	
		HUDIS ET AL, 5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women with High-Risk Node-Positive Breast Cancer: A Phase II Study, Journal of Clinical Oncology, 1999, Page(s) 1118-1126, Volume 17, Number 4	
		HUDIS ET AL, Sequential Adjuvant Therapy with Doxorubicin/Paclitaxel/Cyclophosphamide for Resectable Breast Cancer Involving Four or More Axillary Nodes, Seminars in Oncology, 1995, Page(s) 18-23, Volume 22, Number 6	
		HUDIS ET AL, Sequential Adjuvant Therapy: The Memorial Sloan-Kettering Cancer Center Experience, Seminars in Oncology, 1996, Page(s) 58-64, Volume 23, Number 1	
		HUDIS ET AL, Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy, Journal of Clinical Oncology, 1999, Page(s) 93-100, Volume 17, Number 1	
		HUDIS ET AL, Sequential Single-Agent Chemotherapy Versus Simultaneous Combination Chemotherapy for Primary and Metastatic Breast Cancer, Seminars in Breast Disease, 1999, Page(s) 180-192, Volume 2, Number 2	
		LICHTMAN ET AL, Phase I Trial of Granulocyte-Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 weeks; a Cancer and Leukemia Group B Study, Journal of the National Cancer Institute, 8/18/1993, Page(s) 1319-1326, Volume 85, Number 16	
		MCCAFFREY EL AL; A Phase II and Pharmacologic Study of Taxol (T) by Weekly One-Hour (a-h) Infusion in the Treatment of Patients (pts) with Metastatic Breast Cancer (MBC);1997; Page(s) 234; Number 41	
		NORTON ET AL, Tumor Growth Kinetics, Therapeutic Differentials, and Design of Treatment Schedules, Cancer Treatment Reports, 5/1978, Page(s) 845-847, Volume 62, Number 5	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/735,180	
			Filing Date	12/12/2003	
			First Named Inventor	Norton	
			Art Unit		
			Examiner Name		
Sheet	5	of	9	Attorney Docket Number	MSK.P-067

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NORTON, Thoughts on a Role for Cell Kinetics in Cancer Chemotherapy, Controversies in Cancer: Design of Trials and Treatment, 1979, Page(s) 105-115	
		NORTON, Mathematical Interpretation of Tumor Growth Kinetics, Clinical Interpretation and Practice of Cancer Chemotherapy, 1982, Page(s) 53-70	
		NORTON, A Gompertzian Model of Human Breast Cancer Growth, Cancer Research, 12/15/1988, Page(s) 7067-7071, Volume 48	
		NORTON, Reply to the editor, Cancer Research, 8/9/1989, Page(s) 6444, Volume 49	
		NORTON, Biology of Residual Breast Cancer after Therapy: A Kinetic Interpretation, Program of Clinical Biology Research, 1990, Page(s) 109-132	
		NORTON ET AL., Potential Innovations in Scheduling of Cancer Chemotherapy, Important Advanced Oncology, 1991, Page(s) 57-72	
		NORTON, Clinical Aspects of Cell and Tumor Growth Kinetics, 1991, Page(s) 409-414, Publisher: William & Wilkens	
		NORTON, Tumor Growth Kinetics, Manual of Clinical Oncology, 1991, Page(s) 52-69, Publisher: Elsevier	
		NORTON, Evolving concepts in the adjuvant systemic therapy of operable breast cancer, Cancer Treatment Research, 1992, Page(s) 3-25, Number 60, Publisher: Kluwer Academic Publishers	
		NORTON; The Norton-Simon Hypothesis; 1992; Page(s) 36-53; Publisher: Williams & Wilkins	
		NORTON ET AL, Cytokinetics, Adjuvant Therapy of Primary Breast Cancer IV, 1993, Page(s) 598-617	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/735,180	
			Filing Date	12/12/2003	
			First Named Inventor	Norton	
			Art Unit		
			Examiner Name		
Sheet	6	of	9	Attorney Docket Number	MSK.P-067

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NORTON, Kinetic Concepts in the Treatment of Breast Cancer, Recent Results in Cancer Research, 1993, Page(s) 1-6, Volume 127	
		NORTON, The Norton-Simon Hypothesis, The Chemotherapy Source Book, 1996, Page(s) 43-61	
		NORTON, Conceptual Basis for Advances in the Systemic Drug Therapy of Breast Cancer, Seminars in Oncology, 1997, Page(s) S11-2 - S11-12, Volume 24, Number 4	
		NORTON, Evolving Concepts in the Systemic Drug Therapy of Breast Cancer, Seminars in Oncology, 1997, Page(s) S10-3 - S10-10, Volume 24, Number 4	
		NORTON, Integration of New Therapies into the Management of Breast Cancer, Oncology, 1998, Page(s) 1-4, Volume 12, Number 1	
		NORTON, Kinetic Concepts in the Systemic Drug Therapy of Breast Cancer, Seminars in Oncology, 1999, Page(s) 11-20, Volume 26, Number 1	
		NORTON, Adjuvant Breast Cancer Therapy: Current Status and Future Strategies-Growth Kinetics and the Improved Drug Therapy of Breast Cancer, Seminars in Oncology, 1999, Page(s) 1-4, Volume 26, Number 1	
		NORTON, Chemotherapy Dose, Schedule, and the Modern Treatment of Primary Breast Cancer, Cancer Investigation, 2000, Page(s) 55-57	
		NORTON, Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant Therapy, The Oncologist, 2001, Page(s) 30-35, Volume 6, Number 3	
		NORTON, Salvage Chemotherapy of Breast Cancer; Seminars in Oncology; 1994, Page(s) 19-24, Volume 21, Number 4	
		NORTON ET AL, Innovative approaches to the treatment of advanced breast cancer: introduction, Seminars in Oncology, 1997, Page(s) S101-S102, Volume 24, Number 4	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet	7	of	9
		Attorney Docket Number	MSK,P-067

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NORTON, Introduction to Clinical Aspects of Preneoplasia: a Mathematical Relationship between Stromal Paracrine Autonomy and Population Size, 1993, Page(s) 269-275, Publisher: Ares-Serono Symposia Publications	
		NORTON, Larry Norton-President-elect of ASCO, Lancet Oncology, 2000, Page(s) 189-192, Volume 1	
		NORTON ET AL, Tumor Size, Sensitivity to Therapy, and Design of Treatment Schedules, Cancer Treatment Reports, 10/1977, Page(s) 1307-1317, Volume 61, Number 7	
		NORTON, Implications of Kinetic Heterogeneity in Clinical Oncology, Seminars in Oncology, 9/1985, Page(s) 231-249, Volume 12, Number 3	
		NORTON ET AL, Predicting the course of Gompertzian growth, Nature, 12/9/1976, Page(s) 542-545, Volume 264	
		NORTON ET AL, Growth Curve of an Experimental Solid Tumor Following Radiotherapy, J National Cancer Institute, 1977, Page(s) 1735-1741, Volume 58, Number 6	
		NORTON ET AL, New Thoughts on the Relationship of Tumor Growth Characteristics to Sensitivity to Treatment, Methods in Cancer Research, 1979, Page(s) 53-91, Volume XVII	
		NORTON, Cell Kinetics in Normal Tissues and in Tumors of the Young, Cancer in the Young, 1982, Page(s) 53-82	
		NORTON, Tumor Growth Kinetics, The Mount Sinai Journal of Medicine, 3/1985, Page(s) 161-164, Volume 52, Number 3	
		NORTON ET AL, The Norton-Simon Hypothesis Revisited, 1/1986, Page(s) 163-168, Volume 70, Number 1	
		PERLOFF ET AL, Postsurgical Adjuvant Chemotherapy of Stage II Breast Carcinoma with or without Crossover to a Non-Cross-Resistant Regimen: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, 1996, Page(s) 1589-1598, Volume 14, Number 5	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet 8	of 9	Attorney Docket Number	MSK.P-067

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RAPTIS ET AL, Rapid Hematologic Recovery Following CD34+ Selected Versus Unselected Peripheral Blood Progenitor Cell (PBPC) + Filgrastim (G) Rescue of Sequential High Dose Chemotherapy (HDC) in Patients (PTS) with Metastatic Breast Cancer (MBC), Blood, 1995, Page(s) 1601, Volume 86	
		REICHMAN ET AL, Paclitaxel and Recombinant Human Granulocyte Colony-Stimulating Factor as Initial Chemotherapy for Metastatic Breast Cancer, Journal of Clinical Oncology, 1993, Page(s) 1943-1951, Volume 11, Number 10	
		REICHMAN ET AL, Taxol and Recombinant Human Granulocyte Colony-Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer, Pisa Symposia in Oncology: From Biology to Therapy, 1993, Page(s) 398-401, Volume 698	
		SCHER ET AL, Chemotherapy for Urothelial Tract Malignancies: Breaking the Deadlock, Seminars in Surgical Oncology, 1992, Page(s) 316-341, Volume 8	
		SEIDMAN ET AL, Preliminary Experience with Paclitaxel (TAXOL) Plus Recombinant Human Granulocyte Colony-Stimulating Factor in the Treatment of Breast Cancer, Seminars in Oncology, 1993, Page(s) 40-45, Volume 20, Number 4	
		SEIDMAN, Taxol plus recombinant human granulocyte colony stimulating factor as salvage chemotherapy for metastatic breast cancer, Cancer Treatment Update, 1994, Page(s) 172-175	
		SEIDMAN ET AL, Taxol (Paclitaxel) plus Recombinant Human Granulocyte Colony-Stimulating Factor in the Treatment of Metastatic Breast Cancer, Oncology, 1994, Page(s) 33-39, Volume 51	
		SEIDMAN ET AL, Phase II Trial of Weekly 1-Hour Taxol and Herceptin for Metastatic Breast Cancer: Toward Further Exploitation of Proven Synergistic Antitumor Activity, Cancer Investigation, 1999, Page(s) 44-45, Volume 17	
		SEIDMAN, Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer with Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification, Journal of Clinical Oncology, 2001, Page(s) 2587-2595, Volume 19, Number 10	
		SEIDMAN ET AL, Dose-Dense Therapy with Paclitaxel Via Weekly 1-Hour Infusion: Preliminary Experience in the Treatment of Metastatic Breast Cancer, 1997, Page(s) S17-72 - S17-76, Volume 24, Number 5	
		SEIDMAN ET AL, Dose-Dense Therapy with Weekly 1-Hour Paclitaxel Infusions in the Treatment of Metastatic Breast Cancer, Journal of Clinical Oncology, 1998, Page(s) 3353-3361, Volume 16, Number 10	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,180
		Filing Date	12/12/2003
		First Named Inventor	Norton
		Art Unit	
		Examiner Name	
Sheet	9	of	9
		Attorney Docket Number	MSK,P-067

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SURBONE ET AL, Kinetic Concepts in the Treatment of Breast Cancer, Pisa Symposia in Oncology: From Biology to Therapy, 1993, Page(s) 48-62, Volume 698	
		SURBONE ET AL, Le basi cinetiche delle neoplasie mammarie, Minerva Medica, 1994, Page(s) 7-16, Volume 85, Number 1-2	
		SURBONE ET AL, Cytokinetics, Cancer Medicine 4th edition, 1996, Page(s) 769-798	
		VAHDAT ET AL, Rapidly Cycled Courses of High-Dose Akylating Agents Supported by Filgrastim and Peripheral Blood Progenitor Cells in Patients with Metastatic Breast Cancer, Clinical Cancer Research, , Page(s) 1267-1273, Volume 1	
		WINER ET AL, A Randomized Trial of Three Doses of Paclitaxel in Patients with Metastatic Breast Cancer, Seminar in Oncology, 1999, Page(s) 9, Volume 26	
		WOOD ET AL, Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma, The New England Journal of Medicine, 5/5/1994, Page(s) 1253-1259, Volume 330, Number 18	
		YORKE ET AL, Modeling the Development of Metastases from Primary and Locally Recurrent Tumors: Comparison with a Clinical Data Base for Prostatic Cancer, Cancer Research, 7/1/1993, Page(s) 2987-2993, Volume 53	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.